Celecoxib

DRUG INFORMATION

  ADULT
    - • Use the lowest effective dosage for shortest duration consistent with individual
      patient treatment goals ( 2.1 ) • OA: 200 mg once daily or 100 mg twice daily (
      2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) • JRA: 50 mg twice
      daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg (
      2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily.
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29
    - If no effect is observed after 6 weeks, a trial of 400 mg (single or divided
      doses) may be of benefit ( 2.5 , 14.4 ) • AP and PD: 400 mg initially, followed by
      200 mg dose if needed on first day.
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29
    - For patients ≥10 kg to ≤25 kg the recommended dose is 50 mg twice daily.
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Celecoxib capsules are approved for relief of the signs and symptoms of Juvenile
      Rheumatoid Arthritis in patients 2 years and older. Safety and efficacy have not
      been studied beyond six months in children.
      Source: US FDA label for celecoxib (celecoxib), section 'pediatric use', retrieved
      2026-08-29
    - • Use the lowest effective dosage for shortest duration consistent with individual
      patient treatment goals ( 2.1 ) • OA: 200 mg once daily or 100 mg twice daily (
      2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) • JRA: 50 mg twice
      daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg (
      2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily.
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29
    - On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic
      Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment
      (Child-Pugh Class B).
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - The use of celecoxib capsules in patients with severe hepatic impairment is not
      recommended [ see Dosage and Administration ( 2.6 ) and Clinical Pharmacology (
      12.3 ) ]. 8.7 Renal Insufficiency Celecoxib capsules are not recommended in
      patients with severe renal insufficiency [ see Warnings and Precautions ( 5.6 )
      and Clinical Pharmacology ( 12.3 ) ].
      Source: US FDA label for celecoxib (celecoxib), section 'use in specific
      populations', retrieved 2026-08-29
    - Hyperkalemia Increases in serum potassium concentration, including hyperkalemia,
      have been reported with use of NSAIDs, even in some patients without renal
      impairment.
      Source: US FDA label for celecoxib (celecoxib), section 'warnings and cautions',
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic
      Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment
      (Child-Pugh Class B).
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29
    - On subsequent days, the recommended dose is 200 mg twice daily as needed. 2.7
      Special Populations Hepatic Impairment In patients with moderate hepatic
      impairment (Child-Pugh Class B), reduce the dose by 50%.
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29
    - The use of celecoxib capsules in patients with severe hepatic impairment is not
      recommended [ see Warnings and Precautions ( 5.5 ), Use in Specific Populations (
      8.6 ), and Clinical Pharmacology ( 12.3 ) ].
      Source: US FDA label for celecoxib (celecoxib), section 'dosage and
      administration', retrieved 2026-08-29

  PREGNANCY
    - Pregnancy category D from 30 weeks of gestation onward.
      Source: US FDA label for celecoxib (celecoxib), section 'pregnancy', retrieved
      2026-08-29
    - Risk Summary Use of NSAIDs, including celecoxib capsules, during the third
      trimester of pregnancy increases the risk of premature closure of the fetal ductus
      arteriosus.
      Source: US FDA label for celecoxib (celecoxib), section 'pregnancy', retrieved
      2026-08-29
    - Avoid use of NSAIDs, including celecoxib capsules, in pregnant women starting at
      30 weeks of gestation.
      Source: US FDA label for celecoxib (celecoxib), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Infertility Females Based on the mechanism of action, the use of prostaglandin-
      mediated NSAIDs, including celecoxib capsules, may delay or prevent rupture of
      ovarian follicles, which has been associated with reversible infertility in some
      women.
      Source: US FDA label for celecoxib (celecoxib), section 'nursing mothers',
      retrieved 2026-08-29
    - Published animal studies have shown that administration of prostaglandin synthesis
      inhibitors has the potential to disrupt prostaglandin mediated follicular rupture
      required for ovulation.
      Source: US FDA label for celecoxib (celecoxib), section 'nursing mothers',
      retrieved 2026-08-29
    - Small studies in women treated with NSAIDs have also shown a reversible delay in
      ovulation.
      Source: US FDA label for celecoxib (celecoxib), section 'nursing mothers',
      retrieved 2026-08-29